RHEUMATOID arthritis risk criteria may help identify which patients with arthralgia are most likely to progress.
Rheumatoid Arthritis Risk Criteria Developed for Arthralgia
A joint expert committee developed and validated new EULAR/American College of Rheumatology risk stratification criteria for people in secondary care with arthralgia considered to be at risk of rheumatoid arthritis. The aim was to create a standardized method to define risk of progression before clinically apparent inflammatory arthritis develops.
The criteria were derived using data from 2,293 symptomatic at-risk individuals across 10 arthralgia cohorts, including patients with clinically suspect arthralgia and autoantibody positive arthralgia. Investigators focused primarily on progression to clinically apparent inflammatory arthritis within one year. Development of rheumatoid arthritis according to the 2010 EULAR/American College of Rheumatology criteria within one year was assessed as a secondary outcome.
Clinical and Serologic Variables Drive Rheumatoid Arthritis Prediction
The final rheumatoid arthritis risk stratification model included six clinical and serologic variables: morning stiffness, patient reported joint swelling, difficulty making a fist, C reactive protein, rheumatoid factor, and anti-citrullinated peptide antibody. This model achieved an area under the curve of 0.80 with a 95% confidence interval of 0.77–0.83 for prediction of inflammatory arthritis development within one year.
Ultrasound detected variables did not improve discriminative performance. By contrast, the addition of MRI detected subclinical inflammation increased the area under the curve to 0.87 with a 95% confidence interval of 0.82–0.90. When clinical, serologic, and MRI variables were considered together, both sensitivity and specificity exceeded 75%.
For rheumatoid arthritis development specifically, the criteria that included MRI performed even more strongly, yielding an area under the curve of 0.93 with a 95% confidence interval of 0.90–0.97.
Defining Homogeneous Risk Groups for Future Trials
The authors concluded that these rheumatoid arthritis risk criteria can be used in people with arthralgia who are considered at risk in secondary care, whether imaging data are available or not. Importantly, the criteria were designed to define more homogeneous risk groups, which may support future prevention trials and improve how at-risk patients are categorized in research settings.
Rather than functioning solely as a diagnostic tool, the new framework marks a step toward a more structured pre-arthritis risk stage, where clinical symptoms, serologic findings, and MRI evidence can be combined to better estimate short term progression.
Reference
van Steenbergen HW et al. EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia. Arthritis Rheumatol. 2026;78(3):523-536.
Featured Image: David Sarzosa on Adobe Stock.
